Welcome to LookChem.com Sign In|Join Free

CAS

  • or

7703-74-4

Post Buying Request

7703-74-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

7703-74-4 Usage

Description

2,6-Bis(bromomethyl)pyridine is an organic compound with the molecular formula C6H6Br2N. It is a crystalline solid that is used as a synthetic intermediate in the preparation of various chemical compounds and ligands. The crystal structure of this compound features a c-glide-plane operation, with molecules arranged into stacks along the c axis.

Uses

1. Used in the preparation of new pyridine-pyrazole derivatives:
2,6-Bis(bromomethyl)pyridine is used as a synthetic intermediate for the creation of new pyridine-pyrazole derivatives, such as 2,6-bis(3,5-diphenylpyrazol-1-ylmethyl)pyridine. These derivatives have potential applications in various fields, including pharmaceuticals and materials science.
2. Used in the synthesis of large macrocyclic ligands:
In the field of coordination chemistry, 2,6-bis(bromomethyl)pyridine is utilized as a building block for the synthesis of large macrocyclic ligands, such as N(1),N(7)-pyridine-2,6-dimethyl-N(2),N(6)-bis(6-(3-(1H-benzo[d]imidazol-1-yl)propanamido)pyridin-2-yl)pyridine-2,6-dicarboxamide dibromide. These macrocyclic ligands are valuable for their ability to form stable complexes with metal ions, which can be used in catalysis, sensing, and other applications.
3. Used in the synthesis of small-ring, potentially tridentate Se(2)N(pyridyl)-donor macrocycles:
2,6-Bis(bromomethyl)pyridine is also employed in the synthesis of small-ring macrocycles with potential tridentate Se(2)N(pyridyl)-donor properties. These macrocycles can be used in the development of new coordination complexes and have potential applications in various fields, such as catalysis and supramolecular chemistry.
4. Used in the synthesis of dicationic imidazolium-linked cyclophane:
Additionally, 2,6-bis(bromomethyl)pyridine is involved in the synthesis of dicationic imidazolium-linked cyclophane, which is a type of cyclic compound with potential applications in the development of novel materials and catalysts.

Check Digit Verification of cas no

The CAS Registry Mumber 7703-74-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,7,0 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 7703-74:
(6*7)+(5*7)+(4*0)+(3*3)+(2*7)+(1*4)=104
104 % 10 = 4
So 7703-74-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H7Br2N/c8-4-6-2-1-3-7(5-9)10-6/h1-3H,4-5H2

7703-74-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (405426)  2,6-Bis(bromomethyl)pyridine  98%

  • 7703-74-4

  • 405426-1G

  • 730.08CNY

  • Detail
  • Aldrich

  • (405426)  2,6-Bis(bromomethyl)pyridine  98%

  • 7703-74-4

  • 405426-5G

  • 2,384.46CNY

  • Detail

7703-74-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,6-Bis(bromomethyl)pyridine

1.2 Other means of identification

Product number -
Other names 2,6-BIS(BROMOMETHYL)PYRIDINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:7703-74-4 SDS

7703-74-4Synthetic route

2.6-bis(hydroxymethyl)pyridine
1195-59-1

2.6-bis(hydroxymethyl)pyridine

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
Stage #1: 2.6-bis(hydroxymethyl)pyridine With hydrogen bromide In water at 125℃;
Stage #2: With sodium hydrogencarbonate In water pH=8;
96%
With hydrogen bromide In water at 125℃; for 6h; Inert atmosphere;96%
With phosphorus tribromide In N,N-dimethyl-formamide at 0 - 20℃; for 4h;95%
2,6-dimethylpyridine
108-48-5

2,6-dimethylpyridine

1,3-dibromo-2-hydroxypropane
96-21-9

1,3-dibromo-2-hydroxypropane

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
With 2,2'-azobis(isobutyronitrile) In tetrachloromethane at 80℃; for 24h; Reagent/catalyst;95%
2.6-bis(hydroxymethyl)pyridine
1195-59-1

2.6-bis(hydroxymethyl)pyridine

phosphorus tribromide
7789-60-8

phosphorus tribromide

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 0 - 20℃; Inert atmosphere;91%
2,6-dimethylpyridine
108-48-5

2,6-dimethylpyridine

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
With 2,2'-azobis(isobutyronitrile); bromine; nitric acid In dichloromethane for 5h; Reflux;86.5%
With 2,2'-azobis(isobutyronitrile); bromine In dichloromethane for 5h; Reflux;84.8%
Stage #1: 2,6-dimethylpyridine With N-Bromosuccinimide; dibenzoyl peroxide In tetrachloromethane Heating;
Stage #2: With Diethyl phosphonate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 25℃; for 5h;
76%
2.6-bis(hydroxymethyl)pyridine
1195-59-1

2.6-bis(hydroxymethyl)pyridine

A

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

B

(6-(bromomethyl)pyridin-2-yl)methanol
40054-01-1

(6-(bromomethyl)pyridin-2-yl)methanol

Conditions
ConditionsYield
With hydrogen bromide for 15h; Heating;A 51%
B 24%
With hydrogen bromide for 17h; Heating;A 41%
B 44%
With hydrogen bromide Heating;A 27%
B 41%
With hydrogen bromide for 1h; Heating;A 11%
B 39%
2,6-dimethylpyridine
108-48-5

2,6-dimethylpyridine

phenyllithium
591-51-5

phenyllithium

A

2-(bromomethyl)-6-methylpyridine
68470-59-7

2-(bromomethyl)-6-methylpyridine

B

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
With diethyl ether anschliessend Behandeln mit Brom;
2,6-dimethylpyridine
108-48-5

2,6-dimethylpyridine

A

2-(bromomethyl)-6-methylpyridine
68470-59-7

2-(bromomethyl)-6-methylpyridine

B

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
With tetrachloromethane; N-Bromosuccinimide; dibenzoyl peroxide
2,6-bis(methoxycarbonyl)pyridine
5453-67-8

2,6-bis(methoxycarbonyl)pyridine

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium tetrahydroborate / ethanol / 13 h / 0 - 20 °C / Reflux
2: hydrogen bromide / 15 h / Reflux
View Scheme
Multi-step reaction with 2 steps
1: sodium tetrahydroborate / tetrahydrofuran / 16 h / 20 °C / Inert atmosphere
2: hydrogen bromide; acetic acid / 1.5 h / 100 °C / Inert atmosphere
View Scheme
Multi-step reaction with 2 steps
1: methanol; sodium tetrahydroborate / Inert atmosphere; Reflux
2: hydrogen bromide; acetic acid / 1.5 h / 100 °C / Inert atmosphere
View Scheme
Pyridine-2,6-dicarboxylic acid
499-83-2

Pyridine-2,6-dicarboxylic acid

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: ethanolic HCl
2: lithium alanate; diethyl ether
3: sulfuric acid; aqueous hydrobromic acid
View Scheme
Multi-step reaction with 3 steps
1: thionyl chloride / 5 h / 0 °C / Reflux; Inert atmosphere
2: sodium tetrahydroborate / tetrahydrofuran / 16 h / 20 °C / Inert atmosphere
3: hydrogen bromide; acetic acid / 1.5 h / 100 °C / Inert atmosphere
View Scheme
Multi-step reaction with 3 steps
1.1: thionyl chloride / 6 h / -20 - 20 °C
2.1: sodium tetrahydroborate / tetrahydrofuran / 10 h / 20 °C / Inert atmosphere
2.2: pH Ca. 3
2.3: pH Ca. 9
3.1: hydrogen bromide / water / 10 h / Reflux
3.2: pH Ca. 9
View Scheme
Multi-step reaction with 3 steps
1: thionyl chloride / 18 h / Inert atmosphere; Reflux
2: methanol; sodium tetrahydroborate / Inert atmosphere; Reflux
3: hydrogen bromide; acetic acid / 1.5 h / 100 °C / Inert atmosphere
View Scheme
Multi-step reaction with 3 steps
1: sulfuric acid / 8 h / Reflux
2: sodium tetrahydroborate / tetrahydrofuran / 12 h / 20 °C / Cooling with ice
3: phosphorus tribromide / diethyl ether / 4.5 h / 0 °C / Reflux
View Scheme
diethyl-2,6-pyridinedicarbonyl ester

diethyl-2,6-pyridinedicarbonyl ester

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: lithium alanate; diethyl ether
2: sulfuric acid; aqueous hydrobromic acid
View Scheme
Multi-step reaction with 2 steps
1.1: sodium tetrahydroborate / tetrahydrofuran / 10 h / 20 °C / Inert atmosphere
1.2: pH Ca. 3
1.3: pH Ca. 9
2.1: hydrogen bromide / water / 10 h / Reflux
2.2: pH Ca. 9
View Scheme
Multi-step reaction with 2 steps
1: sodium tetrahydroborate / tetrahydrofuran / 12 h / 20 °C / Cooling with ice
2: phosphorus tribromide / diethyl ether / 4.5 h / 0 °C / Reflux
View Scheme
2.6-bis(hydroxymethyl)pyridine
1195-59-1

2.6-bis(hydroxymethyl)pyridine

concentrated H2 SO4

concentrated H2 SO4

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
In hydrogen bromide
6-acetyl-2-pyridinecarboxylic acid
122637-39-2

6-acetyl-2-pyridinecarboxylic acid

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: thionyl chloride
2: sodium tetrahydroborate / ethanol / 13 h / 0 - 20 °C / Reflux
3: hydrogen bromide / 15 h / Reflux
View Scheme
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

triethyl phosphite
122-52-1

triethyl phosphite

tetraethyl 2,6-bis(methanephosphonate)pyridine
61973-87-3

tetraethyl 2,6-bis(methanephosphonate)pyridine

Conditions
ConditionsYield
at 135℃; for 2.5h; Arbuzov Reaction;100%
at 110℃; for 4h;85%
for 15h; Condensation; Arbuzov reaction; Heating;61%
at 135℃; for 2.5h; Arbuzov reaction;
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

cyclen-glyoxal
74199-09-0, 79236-92-3

cyclen-glyoxal

C27H43N9(2+)*2Br(1-)

C27H43N9(2+)*2Br(1-)

Conditions
ConditionsYield
In acetonitrile at 20℃; for 168000h;100%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

C27H43N9(2+)*2Br(1-)

C27H43N9(2+)*2Br(1-)

C34H50N10(4+)*4Br(1-)

C34H50N10(4+)*4Br(1-)

Conditions
ConditionsYield
In acetonitrile at 20℃; for 168000h;100%
1-(2,2'-dimethylpropyl)-1H-imidazole

1-(2,2'-dimethylpropyl)-1H-imidazole

2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

2,6-bis(N-neopentyl-N'-methyleneimidazole)pyridine bromide

2,6-bis(N-neopentyl-N'-methyleneimidazole)pyridine bromide

Conditions
ConditionsYield
In 1,4-dioxane Reflux;100%
In tetrahydrofuran for 144h; Reflux; Inert atmosphere;
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

C7H13N3
666836-17-5

C7H13N3

2Br(1-)*C21H33N7(2+)

2Br(1-)*C21H33N7(2+)

Conditions
ConditionsYield
In 1,4-dioxane Reflux;100%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

1-butyl-1H-[1,2,4]triazole
6086-22-2

1-butyl-1H-[1,2,4]triazole

2Br(1-)*C19H29N7(2+)

2Br(1-)*C19H29N7(2+)

Conditions
ConditionsYield
In 1,4-dioxane Reflux;100%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

sodium benzenesulfonate
873-55-2

sodium benzenesulfonate

2,6-bis[(phenylsulfonyl)methyl]pyridine

2,6-bis[(phenylsulfonyl)methyl]pyridine

Conditions
ConditionsYield
With tetra-n-propylammonium bromide In acetonitrile for 24h;100%
With tetra-n-propylammonium bromide In acetonitrile for 24h;87%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

2,6-bis(azidomethyl)pyridine
200489-04-9

2,6-bis(azidomethyl)pyridine

Conditions
ConditionsYield
With sodium azide In dimethyl sulfoxide at 20℃; Inert atmosphere;99%
With sodium azide In dimethyl sulfoxide at 20℃; for 2h;98%
With sodium azide In N,N-dimethyl-formamide at 60℃; for 10h;96%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

1-(2,4,6-trimethylphenyl)-4,5-dihydro-1H-imidazole
717110-52-6

1-(2,4,6-trimethylphenyl)-4,5-dihydro-1H-imidazole

2,6-bis((1-mesityl-dihydroimidazolium)methyl)pyridine dibromide

2,6-bis((1-mesityl-dihydroimidazolium)methyl)pyridine dibromide

Conditions
ConditionsYield
In N,N-dimethyl-formamide for 18h;99%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

potassium selenocyanate
3425-46-5

potassium selenocyanate

2,6-bis(selenocyanatomethyl)pyridine
85539-82-8

2,6-bis(selenocyanatomethyl)pyridine

Conditions
ConditionsYield
In acetone Ambient temperature;98%
In acetone for 4h; Ambient temperature;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

tert-butyl iminodiacetate
85916-13-8

tert-butyl iminodiacetate

tetra(tert-butyl) 2,2',2'',2'''-<(pyridine-2,6-diyl)bis(methylenenitrilo)>tetrakis(acetate)
144367-62-4

tetra(tert-butyl) 2,2',2'',2'''-<(pyridine-2,6-diyl)bis(methylenenitrilo)>tetrakis(acetate)

Conditions
ConditionsYield
With sodium carbonate In acetonitrile Heating;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

N-[6-(2-hydroxymethyl)pyridylmethyl]piperazine
196301-00-5

N-[6-(2-hydroxymethyl)pyridylmethyl]piperazine

2,6-bis[N'-[N'-(2-hydroxymethyl-6-pyridylmethyl)]piperazidylmethyl]pyridine
196300-94-4

2,6-bis[N'-[N'-(2-hydroxymethyl-6-pyridylmethyl)]piperazidylmethyl]pyridine

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 4h; Heating;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

(R,R)-N,N'-(cyclohexane-1,2-diyl)-N,N',N'',N'''-tetrakis(p-toluenesulphonyl)bis(propane-1,3-diamine)
223704-14-1

(R,R)-N,N'-(cyclohexane-1,2-diyl)-N,N',N'',N'''-tetrakis(p-toluenesulphonyl)bis(propane-1,3-diamine)

(7R,8R)-7,8-(butane-1,4-diyl)-N,N',N'',N'''-tetrakis(p-toluenesulfonyl)-2,6,9,13-tetraaza[14]-(2,6)-pyridinophane

(7R,8R)-7,8-(butane-1,4-diyl)-N,N',N'',N'''-tetrakis(p-toluenesulfonyl)-2,6,9,13-tetraaza[14]-(2,6)-pyridinophane

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 48h; Heating;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

ethylenediamine
107-15-3

ethylenediamine

2,6-bis(1,4-diazapentyl)pyridine
117013-61-3

2,6-bis(1,4-diazapentyl)pyridine

Conditions
ConditionsYield
Stage #1: 2,6-bis-(bromomethyl)pyridine; ethylenediamine In tetrahydrofuran at 25℃; for 12h;
Stage #2: With potassium hydroxide In methanol
98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

Trimethylenediamine
109-76-2

Trimethylenediamine

2,6-bis[N-(3-aminopropyl)aminomethyl]pyridine
118230-14-1

2,6-bis[N-(3-aminopropyl)aminomethyl]pyridine

Conditions
ConditionsYield
Stage #1: 2,6-bis-(bromomethyl)pyridine; Trimethylenediamine In tetrahydrofuran at 25℃; for 12h;
Stage #2: With potassium hydroxide In methanol
98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

1,4-diaminobutane
110-60-1

1,4-diaminobutane

C15H29N5
1104610-19-6

C15H29N5

Conditions
ConditionsYield
Stage #1: 2,6-bis-(bromomethyl)pyridine; 1,4-diaminobutane In tetrahydrofuran at 25℃; for 12h;
Stage #2: With potassium hydroxide In methanol
98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

2,6-bis{[4-(1-(1S)-benzyloxycarbonylamino-2-phenylethyl)-1H-imidazol-1-yl]methyl}pyridine
1258781-81-5

2,6-bis{[4-(1-(1S)-benzyloxycarbonylamino-2-phenylethyl)-1H-imidazol-1-yl]methyl}pyridine

2Br(1-)*C52H50N8O4(2+)

2Br(1-)*C52H50N8O4(2+)

Conditions
ConditionsYield
In acetone for 144h; Reflux; Inert atmosphere;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

(S)-2-(2-nitrophenylsulfonamido)-N-((1R,2R)-2-(2-nitrophenylsulfonamido)cyclohexyl)-3-phenylpropanamide
1350538-34-9

(S)-2-(2-nitrophenylsulfonamido)-N-((1R,2R)-2-(2-nitrophenylsulfonamido)cyclohexyl)-3-phenylpropanamide

(4R,9R,12S)-12-benzyl-3,13-bis(2-nitrobenzenesulfonyl)-3,10,13,19-tetraazatricyclo[13.3.1.0(4,9)]nonadeca-1(19),15,17-trien-11-one
1350538-37-2

(4R,9R,12S)-12-benzyl-3,13-bis(2-nitrobenzenesulfonyl)-3,10,13,19-tetraazatricyclo[13.3.1.0(4,9)]nonadeca-1(19),15,17-trien-11-one

Conditions
ConditionsYield
Stage #1: (S)-2-(2-nitrophenylsulfonamido)-N-((1R,2R)-2-(2-nitrophenylsulfonamido)cyclohexyl)-3-phenylpropanamide With potassium carbonate In N,N-dimethyl-formamide at 90℃; for 0.5h;
Stage #2: 2,6-bis-(bromomethyl)pyridine In N,N-dimethyl-formamide for 3h; Richman-Atkins cyclization; Reflux;
98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

N,N',4,8,12,16-hexa(p-toluenesulfonyl)-4,8,12,16-tetraazaundecane-1,19-diamine
87265-96-1

N,N',4,8,12,16-hexa(p-toluenesulfonyl)-4,8,12,16-tetraazaundecane-1,19-diamine

1,5,9,13,17,21-hexakis(p-tolylsulfonyl)-3,7,11,15,19,23-hexaaza-1(2,6)-pyridina cyclotetracosaphane
1448855-81-9

1,5,9,13,17,21-hexakis(p-tolylsulfonyl)-3,7,11,15,19,23-hexaaza-1(2,6)-pyridina cyclotetracosaphane

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 20h; Reflux;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

2,2-dimethylpropylamine
5813-64-9

2,2-dimethylpropylamine

2,6-bis[(neo-pentylamino)methyl]pyridine

2,6-bis[(neo-pentylamino)methyl]pyridine

Conditions
ConditionsYield
at 20℃; for 17h; Inert atmosphere; Schlenk technique; Glovebox;98%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

naphtho[2,3-d]imidazole
269-07-8

naphtho[2,3-d]imidazole

1-((6-((1H-naphtho[2,3-d]imidazol-1-yl)methyl)pyridin-2-yl)methyl)-1H-naphtho[2,3-d]imidazole

1-((6-((1H-naphtho[2,3-d]imidazol-1-yl)methyl)pyridin-2-yl)methyl)-1H-naphtho[2,3-d]imidazole

Conditions
ConditionsYield
With caesium carbonate In N,N-dimethyl-formamide at 20℃;98%
With tetrabutylammomium bromide; potassium carbonate In water; toluene at 20℃; for 8h; Solvent; Temperature; Reagent/catalyst;90%
Stage #1: naphtho[2,3-d]imidazole With tetrabutylammomium bromide; potassium hydroxide In water; toluene
Stage #2: 2,6-bis-(bromomethyl)pyridine In water; toluene at 20℃;
71%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

tert-butylamine
75-64-9

tert-butylamine

N,N′-(pyridine-2,6-diylbis(methylene))bis(2-methylpropan-2-amine)

N,N′-(pyridine-2,6-diylbis(methylene))bis(2-methylpropan-2-amine)

Conditions
ConditionsYield
In chloroform at 50℃; for 5h;97%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

(R)-5-phenyl-6,7-dihydro-5H-pyrrolo-[1,2-c]imidazole
1220532-30-8

(R)-5-phenyl-6,7-dihydro-5H-pyrrolo-[1,2-c]imidazole

(R, R)-2,6-bis(5-phenyl-6,7-dihydro-5H-pyrrolo [1,2-c]imidazolium-2-yl)lutidine dibromide

(R, R)-2,6-bis(5-phenyl-6,7-dihydro-5H-pyrrolo [1,2-c]imidazolium-2-yl)lutidine dibromide

Conditions
ConditionsYield
In methanol at 75℃; for 48h; Inert atmosphere;97%
In methanol at 75℃; for 48h; Inert atmosphere;97%
In methanol at 75℃; for 48h; Inert atmosphere;97%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

C28H24N2P(1+)*F6P(1-)

C28H24N2P(1+)*F6P(1-)

C63H55N5P2(4+)*2Br(1-)*2F6P(1-)

C63H55N5P2(4+)*2Br(1-)*2F6P(1-)

Conditions
ConditionsYield
In acetonitrile for 12h; Schlenk technique; Reflux; Inert atmosphere;97%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

2,6-bis(selenocyanatomethyl)pyridine
85539-82-8

2,6-bis(selenocyanatomethyl)pyridine

2,11-diselena<3.3>(2,6)pyridinophane
118336-03-1

2,11-diselena<3.3>(2,6)pyridinophane

Conditions
ConditionsYield
With sodium tetrahydroborate In tetrahydrofuran; ethanol Ambient temperature;96%
With sodium tetrahydroborate In tetrahydrofuran; ethanol for 20h; Ambient temperature;96%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

phenol
108-95-2

phenol

2,6-bis(phenoxymethyl)pyridine
66433-94-1

2,6-bis(phenoxymethyl)pyridine

Conditions
ConditionsYield
With potassium carbonate In acetonitrile Inert atmosphere; Reflux;96%
With potassium carbonate In acetone Heating;65%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

(o-methylbenzylalcohol)chromiumtricarbonyl sodium salt
124913-29-7

(o-methylbenzylalcohol)chromiumtricarbonyl sodium salt

pyridine-2,6-{o-CH2OCH2C6H4(CH3)(Cr(CO)3)}2
124913-25-3, 124990-34-7

pyridine-2,6-{o-CH2OCH2C6H4(CH3)(Cr(CO)3)}2

Conditions
ConditionsYield
In tetrahydrofuran96%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

N,N'-(2S,2'S)-1,1'-(2,2'-oxybis(ethane-2,1-diyl)bis(sulfanediyl))bis(propane-2,1-diyl)bis(4-methylbenzenesulfonamide)

N,N'-(2S,2'S)-1,1'-(2,2'-oxybis(ethane-2,1-diyl)bis(sulfanediyl))bis(propane-2,1-diyl)bis(4-methylbenzenesulfonamide)

(4S,14S)-4,14-dimethyl-3,15-bis-(toluene-4-sulfonyl)-9-oxa-6,12-dithia-3,15,21-triazabicyclo[15.3.1]henicosa-1(20),17(21),18-triene

(4S,14S)-4,14-dimethyl-3,15-bis-(toluene-4-sulfonyl)-9-oxa-6,12-dithia-3,15,21-triazabicyclo[15.3.1]henicosa-1(20),17(21),18-triene

Conditions
ConditionsYield
With caesium carbonate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;96%
2,6-bis-(bromomethyl)pyridine
7703-74-4

2,6-bis-(bromomethyl)pyridine

triphenylphosphine
603-35-0

triphenylphosphine

C43H37Br2NP2

C43H37Br2NP2

Conditions
ConditionsYield
In acetonitrile at 70℃; for 8h;96%

7703-74-4Relevant articles and documents

Free Amino Acid Recognition: A Bisbinaphthyl-Based Fluorescent Probe with High Enantioselectivity

Zhu, Yuan-Yuan,Wu, Xue-Dan,Gu, Shuang-Xi,Pu, Lin

, p. 175 - 181 (2019)

A novel fluorescent probe based on a bisbinaphthyl structure has been designed and synthesized. This compound in combination with Zn(II) has exhibited highly enantioselective fluorescence enhancement with 13 common free amino acids. For example, its enantiomeric fluorescent enhancement ratios (ef or δIL/δID) in the presence of the following amino acids are extremely high: 177 for valine, 199 for methionine, 186 for phenylalanine, 118 for leucine, and 89 for alanine. The observed high enantioselectivity and the extent of the substrate scope are unprecedented in the fluorescent recognition of free amino acids. This fluorescent probe can be applied to determine the enantiomeric composition of the structurally diverse chiral amino acids. NMR and mass spectroscopic investigations have provided clues to elucidate the observed high enantioselectivity.

A one dimensional coordination polymer composed of antiferromagnetically coupled disk-like [Mn7] units

Yang, En-Che,Huang, Han-Sheng,Huang, Shao-Yun,Huang, Shi-Yi,Chang, Yu-Ying,Lee, Gene-Hsiang,Sheu, Hwo-Shuenn,Chang, Chung-Kai

, p. 6963 - 6969 (2018)

The synthesis, characterization by X-ray analysis and magnetic properties of a one dimensional coordination polymer {[Mn7(OH)2(dhap)2(N3)3(MeCN)4(ClO4)2]·2(MeCN)·2(ClO4)}∞ (1) are reported. The ligand dhapH4 in the complex is 2,6-bis[N,N-di(hydroxyethyl)aminomethyl]pyridine. This compound crystallizes in the monoclinic space group C2/c. Each [Mn7(OH)2(dhap)2(N3)3(MeCN)4(ClO4)2] unit (abbreviated by Mn7) is linked end-to-end by azido ligands to its neighboring units to form a one dimensional polymer. Magnetic susceptibility measurements indicate that the polymer is composed of S = 8 units with inter-Mn7-unit antiferromagnetic coupling. The Jahn-Teller axes of the Mn7 units are arranged in a zigzag manner along the polymer chain which induces spin canting at low temperatures. The slow magnetization relaxation at low temperatures was evidenced by observing out-of-phase signals in ac magnetic susceptibility measurements that give Ueff = 47.5 K and Δ0 = 2.7 × 10-13 s. This phenomenon also indicates that this one dimensional coordination polymer functions as a single-chain magnet (SCM).

Synthesis, characterization and X-ray crystal structures of cyclam derivatives. Part VI. Proton binding studies of a pyridine-strapped 5,12-dioxocyclam based macrobicycle

Meyer, Michel,Fremond, Laurent,Tabard, Alain,Espinosa, Enrique,Vollmer, Guy Yves,Guilard, Roger,Dory, Yves

, p. 99 - 108 (2005)

The 14-membered cyclic diamide 1,4,8,11-tetraazacyclotetradecane-5,12-dione (5,12-dioxocyclam) can be considered as a trans-autodiprotected tetraazamacrocycle and provides a convenient starting material for the preparation of macrobicyclic receptors. As an example, the secondary amine nitrogen atoms located at the 1 and 8 positions were cross-bridged with a 1,3-pyridyl strap, affording the constrained ansa-dioxocyclam ligand 1,9,12,18,22-pentaazatricyclo[7.6.6.13,7]docosa-3,5,7(22)-triene-13, 19-dione (L1). The proton binding properties of this cage-type compound, which possesses a hemispherical cavity, were fully investigated by spectroscopic (IR, NMR, UV, MALDI-TOF MS), quantum chemical, and potentiometric methods. While both bridgehead tertiary amines have their free lone pairs oriented inside the cavity, intramolecular hydrogen bonding was found to play a key role in determining the structural features of the free base and its protonated forms. L1 behaves as a diprotic base in water with log K011 = 8.94(1) and log K012 = 2.32(9), but most interestingly shows slow proton-transfer rates on the NMR timescale.

Phosphonated chelates for nuclear imaging

Abada, Sabah,Lecointre, Alexandre,Christine, Cline,Ehret-Sabatier, Laurence,Saupe, Falk,Orend, Gertraud,Brasse, David,Ouadi, Ali,Hussenet, Thomas,Laquerrire, Patrice,Elhabiri, Mourad,Charbonnire, Loc J.

, p. 9601 - 9620 (2014)

A series of bis-, tris- and tetra-phosphonated pyridine ligands is presented. In view of their potential use as chelates for radiopharmaceutical applications, the physico-chemical properties of the ligands and of their Co(ii), Ni(ii), Cu(ii), and Zn(ii) complexes were studied by means of potentiometry and UV-Vis absorption spectroscopy. The pKa values of the ligands and of the complexes, as well as the stability constants for the formation of the complexes, are presented. The kinetic aspects of the formation of Cu(ii) complexes and of their dissociation in acidic media were studied by means of stopped flow experiments, and the stability of the Cu(ii) complex toward reduction to Cu(i) was investigated by cyclic voltammetry and by titration with different reducing agents. The different thermodynamic and kinetic aspects of the polyphosphonated ligands were compared with regard to the impact of the number of phosphonic acid functions. Considering the very promising properties for complexation, preliminary SPECT/CT imaging experiments were carried out on mice with 99mTc using the bis- and tetra-phosphonated ligands L2 and L1. Finally, a bifunctional version of chelate L1, L, was used to label MTn12, a rat monoclonal antibody with both specificity and relatively high affinity for murine tenascin-C. The labeling was monitored by MALDI/MS spectrometry and the affinity of the labeled antibody was checked by immunostaining experiments. After chelation with 99mTc, the 99mTc-L-MTn12 antibody was injected into a transgenic mouse with breast cancer and the biodistribution of the labeled antibody was followed by SPECT/CT imaging.

Synthesis of macrocyclic inclusion complexes using olefin metathesis

Ng, Po Ling,Lambert, John N.

, p. 1749 - 1750 (1999)

The ruthenium-catalysed synthesis of a macrocyclic chelate is described. The reaction proceeds at room temperature using 5% catalyst to afford 4 in 80% isolated yield.

Coordination-driven self-assembly of palladium(II)-based metallacalixarenes as anion receptors using flexible pyridine-bridged diimidazole ligands

Du, Wutong,Tong, Jin,Deng, Wei,Wang, Mingxue,Yu, Shuyan

, p. 485 - 488 (2020/04/15)

Two types of palladium(II)-based metallacalixarenes [ML]2+ and [ML2]2+ have been synthesized through coordination-driven self-assembly from a series of flexible pyridine-bridged diimidazole ligands [2,6-bis((1H-imidazol-1-yl)methyl) pyridine (L1), 2,6-bis((1H-benzo[d]imidazol-1-yl)methyl)pyridine (L2), 2,6-bis((1H-naphtho[2, 3-d]imidazol-1-yl)methyl)pyridine (L3)], with palladium(II)-based building blocks [Pd(BF4)2(M1-BF4) and (tmeda)Pd(NO3)2 (M2-NO3) (tmeda = N,N,N′,N′-tetramethyl-ethylenediamine)]. All complexes were characterized by NMR spectroscopy (1H NMR and 13C NMR), mass spectrometry (CSI-MS, ESI-HRMS) and elemental analysis. The single crystal X-ray diffraction analysis of [M1L22](NO3)2, [M1L32](NO3)2, [M1L32](PF6)2 and [M2L3](NO3)2 further confirmed the uniquely single bowl-shape and double bowl-shape structures. The anion binding properties within the metallacalixarenes as receptors were also investigated by NMR titration experiments in DMSO.

Structural and Thermodynamics Studies on Polyaminophosphonate Ligands for Uranyl Decorporation

Ye, Gaoyang,Roques, Jérome,Solari, Pier-Lorenzo,Den Auwer, Christophe,Jeanson, Aurélie,Brandel, Jérémy,Charbonnière, Lo?c J.,Wu, Wangsuo,Simoni, éric

, p. 2149 - 2159 (2021/02/16)

The development of actinide decorporation agents with high complexation affinity, high tissue specificity, and low biological toxicity is of vital importance for the sustained and healthy development of nuclear energy. After accidental actinide intake, sequestration by chelation therapy to reduce acute damage is considered as the most effective method. In this work, a series of bis- and tetra-phosphonated pyridine ligands have been designed, synthesized, and characterized for uranyl (UO22+) decorporation. Owing to the absorption of the ligand and the luminescence of the uranyl ion, UV-vis spectroscopy and time-resolved laser-induced fluorescence spectroscopy (TRLFS) were used to probe in situ complexation and structure variation of the complexes formed by the ligands with uranyl. Density functional theory (DFT) calculations and X-ray absorption fine structure (XAFS) spectroscopy on uranyl-ligand complexes revealed the coordination geometry around the uranyl center at pH 3 and 7.4. High affinity constants (log K ~17) toward the uranyl ion were determined by displacement titration. A preliminary in vitro chelation study proves that bis-phosphonated pyridine ligands can remove uranium from calmodulin (CaM) at a low dose and in the short term, which supports further uranyl decorporation applications of these ligands.

Functionally Versatile and Highly Stable Chelator for 111In and 177Lu: Proof-of-Principle Prostate-Specific Membrane Antigen Targeting

Li, Lily,Jaraquemada-Peláez, María De Guadalupe,Kuo, Hsiou-Ting,Merkens, Helen,Choudhary, Neha,Gitschtaler, Katrin,Jermilova, Una,Colpo, Nadine,Uribe-Munoz, Carlos,Radchenko, Valery,Schaffer, Paul,Lin, Kuo-Shyan,Bénard, Fran?ois,Orvig, Chris

, p. 1539 - 1553 (2019/05/22)

Here, we present the synthesis and characterization of a new potentially nonadentate chelator H4pypa and its bifunctional analogue tBu4pypa-C7-NHS conjugated to prostate-specific membrane antigen (PSMA)-targeting peptidomimetic (Glu-urea-Lys). H4pypa is very functionally versatile and biologically stable. Compared to the conventional chelators (e.g., DOTA, DTPA), H4pypa has outstanding affinities for both 111In (EC, t1/2 ≈ 2.8 days) and 177Lu (β-,?, t1/2 ≈ 6.64 days). Its radiolabeled complexes were achieved at >98% radiochemical yield, RT within 10 min, at a ligand concentration as low as 10-6 M, with excellent stability in human serum over at least 5-7 days (- complexes (M3+ = In3+, Lu3+, La3+) were dependent on the ionic radii, where the smaller In3+ has the highest pM value (30.5), followed by Lu3+ (22.6) and La3+ (19.9). All pM values are remarkably higher than those with DOTA, DTPA, H4octapa, H4octox, and H4neunpa. Moreover, the facile and versatile bifunctionalization enabled by the p-OH group in the central pyridyl bridge of the pypa scaffold (compound 14) allows incorporation of a variety of linkers for bioconjugation through easy nucleophilic substitution. In this work, an alkyl linker was selected to couple H4pypa to a PSMA-targeting pharmacophore, proving that the bioconjugation sacrifices neither the tumor-targeting nor the chelation properties. The biodistribution profiles of 111In- and 177Lu-labeled tracers are different, but promising, with the 177Lu analogue particularly outstanding.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 7703-74-4